Brokerages Set Humacyte, Inc. (NASDAQ:HUMA) Price Target at $13.71

Shares of Humacyte, Inc. (NASDAQ:HUMA) have earned an average recommendation of “Buy” from the eight ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $13.71.

HUMA has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. BTIG Research reissued a “buy” rating and set a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. D. Boral Capital restated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Monday, January 13th. TD Cowen reiterated a “buy” rating and set a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Finally, Benchmark upped their price objective on shares of Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, December 23rd.

Humacyte Stock Down 1.6 %

NASDAQ HUMA opened at $4.41 on Monday. The company has a 50 day moving average price of $4.58 and a two-hundred day moving average price of $5.66. Humacyte has a 12-month low of $2.53 and a 12-month high of $9.97. The stock has a market capitalization of $555.04 million, a PE ratio of -3.29 and a beta of 1.32.

Insider Buying and Selling

In related news, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the sale, the director now directly owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Laura E. Niklason sold 261,369 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the transaction, the chief executive officer now directly owns 1,730,884 shares of the company’s stock, valued at approximately $7,615,889.60. This trade represents a 13.12 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,500,000 shares of company stock valued at $6,606,799. 11.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Humacyte

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HUMA. State Street Corp increased its holdings in Humacyte by 66.1% during the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after purchasing an additional 1,895,529 shares in the last quarter. Millennium Management LLC increased its stake in shares of Humacyte by 504.3% in the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after buying an additional 1,334,641 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Humacyte by 693.0% in the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after buying an additional 524,600 shares during the last quarter. Marshall Wace LLP lifted its position in Humacyte by 3,301.5% during the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock worth $2,226,000 after buying an additional 450,031 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C bought a new stake in Humacyte during the 2nd quarter worth about $1,550,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.